Goldman Sachs
IMCR icon

Goldman Sachs’s Immunocore IMCR Stock Holding History

Goldman Sachs’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Buy
137,326
+17,829
+15% +$527K ﹤0.01% 3994
2026
Q1 		$3.6M Buy
119,497
+87,107
+269% +$2.82M ﹤0.01% 4006
2025
Q4 		$1.12M Sell
32,390
-26,587
-45% -$939K ﹤0.01% 5054
2025
Q3 		$2.14M Buy
58,977
+14,021
+31% +$476K ﹤0.01% 4414
2025
Q2 		$1.41M Buy
44,956
+13,699
+44% +$426K ﹤0.01% 4444
2025
Q1 		$927K Sell
31,257
-4,782
-13% -$143K ﹤0.01% 4737
2024
Q4 		$1.06M Sell
36,039
-190,302
-84% -$6.02M ﹤0.01% 4778
2024
Q3 		$7.05M Buy
226,341
+136,157
+151% +$4.95M ﹤0.01% 3045
2024
Q2 		$3.06M Sell
90,184
-6,623
-7% -$338K ﹤0.01% 3606
2024
Q1 		$6.29M Buy
96,807
+48,135
+99% +$3.3M ﹤0.01% 2887
2023
Q4 		$3.33M Sell
48,672
-26,633
-35% -$1.38M ﹤0.01% 3512
2023
Q3 		$3.91M Sell
75,305
-12,721
-14% -$753K ﹤0.01% 3205
2023
Q2 		$5.28M Buy
88,026
+47,046
+115% +$2.69M ﹤0.01% 3054
2023
Q1 		$2.03M Sell
40,980
-2,363
-5% -$133K ﹤0.01% 3853
2022
Q4 		$2.47M Buy
+43,343
New +$2.44M ﹤0.01% 3775

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Goldman Sachs's IMCR Position: Q2 2026 in Review

Goldman Sachs increased its Immunocore (IMCR) stake by 15% in Q2 2026, buying an estimated $527K and bringing the position to 137,326 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3994.

Goldman Sachs first reported a position in IMCR in Q4 2022 and has held it in 15 quarters since. The position peaked at $7.05M in Q3 2024. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Goldman Sachs held 137,326 shares of Immunocore worth $4.36M as of Q2 2026.
  • Goldman Sachs bought 17,829 Immunocore shares in Q2 2026, an estimated $527K.
  • Immunocore made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3994 holding.
  • Goldman Sachs first reported a position in Immunocore in Q4 2022 and has held it in 15 quarters since.
  • Goldman Sachs's Immunocore position peaked at $7.05M in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.